The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Investigating the Effects of Pesticide Exposure on Immune System Function in Parkinson’s Disease
Study Rationale: Although it is well known that exposure to environmental substances, including pesticides, contributes considerably to Parkinson’s disease (PD), the mechanisms are largely unexplored...
-
Research Grant, 2024Qualitative Evaluation of Draft Questionnaires for Patient-reported Outcome Measures of Non-motor Symptoms in Early-stage Parkinson's Disease
Study Rationale: This project seeks to address an unmet need for fit-for-purpose, clinical outcome assessments for early-stage Parkinson’s disease (PD) to be used in clinical trials to capture the...
-
Freezing of Gait, 2024Adaptive Cortical Neuromodulation Using a Brain-machine Interface to Treat Freezing of Gait in Parkinson’s Disease
Study Rationale: Difficulties with walking can have significant impacts on the quality of life of people with Parkinson’s (PwP). One of the most serious is freezing of gait (FOG), which are brief but...
-
Freezing of Gait, 2024TURN-IT: A Novel Intervention to Improve Turning in People with PD and Freezing of Gait
Study Rationale: Turning is a critical aspect of mobility for people with PD that, in some individuals, can precipitate freezing of gait. We recently developed a turn-specific intervention for people...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of Novel LRRK2 Inhibitors for the Treatment of Parkinson’s Disease
Study Rationale: Inhibitors of the LRRK2 protein offer promise as a therapy for Parkinson’s disease (PD). The leading inhibitors currently under development, the so-called Type 1 kinase inhibitors...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of a First-in-class Inhibitor of the “Mitochondrial Permeability Transition Pore” as a Novel Disease-modifying Treatment for Parkinson’s Disease
Study Rationale: Mitochondria are subcellular structures that produce energy and help regulate the movement of calcium ions that continually flow into brain cells when they are active, ions that can...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.